American Society of Hematology

Figure 4.

Unstratified hazard ratios. For (A) EFS and (B) PFS in predefined subsets of patients. ABC, activated B cell; ACVBP, doxorubicin (75 mg/m2 at day 1), prednisone (60 mg/m2 day 1 to day 5), cyclophosphamide (1200 mg/m2 at day 1), vindesine (2 mg/m2 at days 1 and 5) and bleomycin (10 mg at days 1 and 5); CHOP, cyclophosphamide (750 mg/m2 at day 1), doxorubicin (50 mg/m2 at day 1), vincristine (1.4 mg/m2, maximum 2 mg, at day 1), and prednisone (40 mg/m2 day 1 to day 5); DE, double expressor; ECOG, Eastern Cooperative Oncology Group scale; GCB, germinal center B cell; LDH, lactate dehydrogenase.

Unstratified hazard ratios. For (A) EFS and (B) PFS in predefined subsets of patients. ABC, activated B cell; ACVBP, doxorubicin (75 mg/m² at day 1), prednisone (60 mg/m² day 1 to day 5), cyclophosphamide (1200 mg/m² at day 1), vindesine (2 mg/m² at days 1 and 5) and bleomycin (10 mg at days 1 and 5); CHOP, cyclophosphamide (750 mg/m² at day 1), doxorubicin (50 mg/m² at day 1), vincristine (1.4 mg/m², maximum 2 mg, at day 1), and prednisone (40 mg/m² day 1 to day 5); DE, double expressor; ECOG, Eastern Cooperative Oncology Group scale; GCB, germinal center B cell; LDH, lactate dehydrogenase.

This Feature Is Available To Subscribers Only